Certified by Founder Lodge
Leaps by Bayer
Germany - Berlin
INVESTOR
1 Disclosed Funding Rounds $100,000,000
9 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Leaps by Bayer invests in paradigm-shifting advances in the life sciences – targeting the breakthroughs that could fundamentally change the world for the better. Our approach is making signif
| Company | Date | Round | Raised |
|---|---|---|---|
 Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
 ReCode Therapeutics |
September, 20 ,2023 | Series B | $50,000,000 |
 NewLeaf Symbiotics, Inc. |
December, 21 ,2023 | Series D | $45,000,000 |
 NextPoint Therapeutics, Inc. |
February, 15 ,2024 | Series B | $42,500,000 |
 9amHealth |
February, 21 ,2024 | Series A | $9,500,000 |
 Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
 Huma |
July, 17 ,2024 | Series D | $80,000,000 |
 GRO Biosciences |
July, 23 ,2024 | Series B | $60,300,000 |
 eGenesis, Inc. |
September, 04 ,2024 | Series B | $191,000,000 |
Wildcat Discovery Technologies
OncoResponse
ResearchHub
DNTOX
F2G | $100,000,000 | (Sep 13, 2024)
Gestalt | $5,900,000 | (Sep 13, 2024)
Safi Biotherapeutics Inc | $5,000,000 | (Sep 13, 2024)
Cohora | $2,500,000 | (Sep 13, 2024)
Cavela | $2,000,000 | (Sep 13, 2024)
